Navigation Links
New Lung Cancer Drug Launched By Roche Pharmaceutical

Major Pharmaceutical Company Roche launched its anti-cancer drug `Tarceva' (erlotinib), which `prolongs and improves' quality of life of patients//, suffering from lung cancer.

The Managing Director Dr G L Telang said, it was an oral tablet taken once a day and has the potential to treat many types of solid tumours therapy for patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) even after failure of at least one prior chemotherapy regiment.

Dr. Telang also said that, the drug has demonstrated a striking survival benefit (42.5 per cent) in advanced non-small cell lung cancer, the most common form of the disease and it has also shown to significantly improve patients' quality of life by reducing the severe and debilitating symptoms that characterise advanced disease, such as cough, pain and breathlessness.

Tarceva works differently to chemotherapy by specifically targeting tumour cells and inhibiting their growth. The drug blocks the tumour cell growth. It acts by inhibiting the activity of a specific enzyme, tyrosine kinase, which is part of the human epidermal growth receptor (EGFR).

Regarding the registration of the drug in the country, they have applied to the government for registration and expect it to come through by the end of this year, he said. Dr.Telang said that the drug will be sold 40 per cent below the international cost and if the government removes the duty on the drug, then the price will be further reduced. He also stated by using the drug, the life of the patient would extends up to a year.

Dr.Telang said, that they were also focusing on trials on earlier stages of NSCLC and in combination with another anti-cancer drug of Roche 'avastin. Trials are also being conducted with Tarceva in other solid tumours like ovarian, bronchioloalveolar and colorectal, head, neck and brain.


'"/>




Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Lung Cancer Drug Launched Roche Pharmaceutical

(Date:3/2/2015)... Today at the State Capitol, Assemblymember ... the California Healthcare Institute (CHI) and the National ... resolution recognizing Feb. 28, 2015 as Rare Disease ... for millions of Californians living with nearly 7,000 ... research organization, representing leading California academic institutions, biotechnology, ...
(Date:3/2/2015)... the Brain Injury Association of America (BIAA) officially kicked off ... the more than 5.3 million Americans who are living with ... in observing Brain Injury Awareness Month by conducting an awareness ... 2015 to 2017 campaign is: Not Alone. , The ... public about the incidence of brain injury and the needs ...
(Date:3/2/2015)... March 02, 2015 A cocaine ... deviating from the typical nip slip or scathing scuffle. ... industry is dawning the streets of Hollywood as Paper ... about drug addiction and substance abuse in Hollywood. The ... to take a political stance on the travails of ...
(Date:3/2/2015)... “ Wants and Needs ” was ... which features the latest and coolest mobile applications on ... mobile technology expert and host of NewsWatch, conducted the ... helps people evaluate priorities. , Whether a person needs ... Needs app. The app allows people to enter and ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 ZoomCare ... to remake American healthcare. Zoom will expand its ... neighborhood clinics and advanced care studios delivering urgent ... emergency services, specialty care and outpatient surgery. With ... access to almost all healthcare needs outside of ...
Breaking Medicine News(10 mins):Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Brain Injury Association of America Launches “Not Alone” Campaign for Brain Injury Awareness Month 2Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 2Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 3Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3
... cancers who receive radical chemoradiation have significantly better ... when compared with patients who have undergone a ... a study in the February 1 issue of ... journal of the American Society for Therapeutic Radiology ...
... The Obesity Action,Coalition (OAC) is calling on the ... 282 (HB 282) that discriminates,against those affected by obesity ... strongly feels that HB 282 is outright discrimination,against the ... attempts,proposed to address the obesity epidemic., Introduced in ...
... play in society, they remain among the most threatened ecosystems ... healthy wetlands for humans, the theme of this years World ... Wetlands, Healthy People. , According to the Ramsar Convention on ... more than 3 million people every year and brings suffering ...
... dance lessons, screenings offered to encourage healthy hearts, ... Month, and Baltimore Washington Medical Center has the key,to ... ), The medical center will host the fourth ... 2008 from 10 a.m. to 3 p.m. at the ...
... of the common Black Rat (Rattus rattus) has shed ... diseases around the globe. , Studying the mitochondrial DNA ... the world, an international team of scientists has identified ... each originating from a different part of Asia. , ...
... Dividend Provides An Annualized Yield Of 9.5%, LARGO, ... Board: UVICF) (TSX Venture Exchange: UVI) Board of Directors,today ... per common,share, payable February 28, 2008 to stockholders of ... "We are pleased to continue the quarterly dividend ...
Cached Medicine News:Health News:Larynx preservation preferred over total laryngectomy 2Health News:Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity 2Health News:Connection between health of wetlands and humans in focus 2Health News:Connection between health of wetlands and humans in focus 3Health News:Baltimore Washington Medical Center Hosts Day of Dance for Health 2Health News:Globetrotting black rat genes reveal spread of humans and diseases 2Health News:Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share 2
(Date:3/2/2015)... March 2, 2015  BC Technical, the nation,s ... acquired Eclipse Systems, a Nuclear Imaging service company ... part of their ongoing vision to provide the ... rate, BC Technical continues to expand their reach ... to add valuable resources and knowledge in addition ...
(Date:3/2/2015)... Calif. , March 2, 2015  DURECT ... its Epigenomic Regulator Program, and the successful completion ... program,s lead product candidate DUR-928.  DUR-928 is an ... have broad applicability in metabolic diseases such as ... (NASH), and in acute organ injuries such as ...
(Date:3/2/2015)... -- Intrexon Corporation (NYSE: XON ), a ... quarter and full year results for 2014.  ... , Acquired ActoGeniX, a European clinical stage biopharmaceutical ... and other innovative products.  Its proprietary TopAct™ platform ... Lactococcus lactis ) to generate biologically-contained ActoBiotics™ for ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24
... 14, 2012  The Consumer Healthcare Products Association (CHPA) ... into law House Bill 2263—anti-meth legislation authored by ... 23rd state to adopt real-time, stop-sale technology known ... The proven system—in a process similar ...
... SCHLIEREN-ZURICH, Switzerland, May 14, 2012 The ALS ... it has entered into collaboration with Neurotune ... Neuron or Lou Gehrig,s disease). (Photo: ... "Maintaining the health of motor neurons ...
Cached Medicine Technology:CHPA Applauds Arizona's Adoption Of HB 2263 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 3
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Centra-GP6R general purpose centrifuges offer high-volume versatility ... rotor options, making them ideal for a ... Versatility , Four- or six-place sealed ... oil tube rotors offered , Lare capacity ...
... Centrifuges feature powerful, maintenance-free motors, ... of rotors for unparalleled application ... in one: a high capacity ... harvesting; a high-speed centrifuge for ...
... MicroCentrifuge Two Strip Rotor hold 16 0.2ml ... with). Simply close the polycarbonate lid to ... open. Starts and stops in seconds. Maximum ... g. Only five inches in diameter. Also ...
Medicine Products: